Drug Trial Radar · NCT05669599
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Jan 18, 2023
Primary completion
Oct 8, 2024
Study completion Dec 16, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).
Conditions
- Obesity
- Overweight
- Type 2 Diabetes Mellitus
Interventions
Maridebart CafraglutideBiological
Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
PlaceboDrug
Participants will receive placebo by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 52 in Body WeightTime frame: Baseline and Week 52
Locations
78 sites in 12 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research Mobile
Mobile, Alabama
Foothills Research Center
Phoenix, Arizona
HonorHealth
Scottsdale, Arizona
Ark Clinical Research- Long Beach
Long Beach, California
Ark Clinical Research- Tustin
Tustin, California
Orange County Research Center
Tustin, California
Diablo Clinical Research
Walnut Creek, California
Alliance for Multispecialty Research Miami
Coral Gables, Florida
Progressive Medical Research
Port Orange, Florida
East-West Medical Research
Honolulu, Hawaii
University of Chicago
Chicago, Illinois
Great Lakes Clinical Trials
Chicago, Illinois
Alliance for Multispecialty Research Newton
Newton, Kansas
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky
Tandem Clinical Research - Marrero
Marrero, Louisiana
StudyMetrix Research
City of Saint Peters, Missouri
Alliance for Multispecialty Research Kansas City
Kansas City, Missouri
State University of New York Upstate Medical University
Syracuse, New York
Lucas Research
Morehead City, North Carolina
Research Innovations LLC dba Internal Medicine Care Inc
Beavercreek, Ohio
The Christ Hospital
Cincinnati, Ohio
Alliance for Multispecialty Research Norman
Norman, Oklahoma
Medical Care LLC
Elizabethton, Tennessee
PanAmerican Clinical Research LLC
Brownsville, Texas
Headlands Research Brownsville
Brownsville, Texas
Clinical Trials of Texas
San Antonio, Texas
Diabetes and Glandular Disease Clinic
San Antonio, Texas
Pinnacle Clinical Research
San Antonio, Texas
Texas Diabetes Institute
San Antonio, Texas
Royal Prince Alfred Hospital (RPAH) Clinic
Camperdown, New South Wales, Australia
Clinical Medical and Analytical eXellence CMAX
Adelaide, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
Austin Health, Heidelberg Repatriation Hospital
Heidelberg Heights, Victoria, Australia
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia
University of Calgary
Calgary, Alberta, Canada
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Centricity Research Vaughan Endocrinology
Concord, Ontario, Canada
Institut Universitaire de cardiologie et de pneumologie de Quebec
Québec, Quebec, Canada
Clinique des Maladies Lipidiques de Quebec Incorporated
Québec, Quebec, Canada
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.